Proteolysis-targeting chimeras (PROTACs) have been an area of intensive research with the
potential to extend drug space not target to traditional molecules. In the last half decade, we …

Targeted protein degradation (TPD) technologies, particularly proteolysis-targeting chimeras
(PROTACs), have emerged as a significant advancement in drug discovery. However …

The importance of EZH2 as a key methyltransferase has been well documented
theoretically. Practically, the first EZH2 inhibitor Tazemetostat (EPZ6438), was approved by …

Sarcomas are heterogeneous bone and soft tissue cancers representing the second most
common tumor type in children and adolescents. Histology and genetic profiling discovered …

The scientific community has shown considerable interest in proteolysis-targeting chimeras
(PROTACs) in the last decade, indicating their remarkable potential as a means of achieving …

The absence of effective active pockets makes traditional molecularly targeted drug
strategies ineffective against 80% of human disease-related proteins. The PROTAC …

Ferroptosis is a novel form of oxidative cell death triggered by iron-dependent lipid
peroxidation. The induction of ferroptosis presents an attractive therapeutic strategy for …

Small molecule heterobifunctional degraders (commonly also known as PROTACs) offer
tremendous potential to deliver new therapeutics in areas of unmet medical need. To deliver …

Advancements in anticancer strategies spotlight proteolysis targeting chimera (PROTAC)
technology, yet it is hindered by poor water solubility and bioavailability. This study …

Selective degradation of disease-causing proteins using proteolysis targeting chimeras
(PROTACs) has gained great attention, thanks to its several advantages over traditional …